Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1453 • ACR Convergence 2023
Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts
Rashmi Dhital¹, Maria Dall'Era² and Kenneth Kalunian³, ¹UC San Diego, San Diego, CA, ²University of California San Francisco, San Francisco, CA, ³University of California San Diego, La Jolla, CA
Background/Purpose: Musculoskeletal manifestations of systemic lupus erythematosus (SLE) are common, consisting ofarthralgia and arthritis (95%), myalgia/myositis (17%), tenosynovitis, and bursitis (12%). Joint involvement is a…
Abstract Number: 1470 • ACR Convergence 2023
SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study
Eun song Kang¹ and Yong-Gil Kim², ¹Korea University Ansan Hospital, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background/Purpose: Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to…
Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Jinoos Yazdany² and Maria Dall'Era³, ¹University of California San Francisco, San Rafael, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…
Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Vasileios Kyttaris¹, Gelareh Atefi², Daniel Persons³, Christopher S. Ambrose⁴, Scott Milligan⁵ and Sandra Wu⁶, ¹BIDMC, Boston, MA, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³Trio Health, Denver, CO, ⁴AstraZeneca, Wilmington, DE, ⁵Trio Health, Analytics, Louisville, CO, ⁶AstraZeneca, Hockessin, DE
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…
Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Lola Torz², Natalia Petersen², Ayal Ben-Zvi³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Novo Nordic, Global Obesity Research, Malov, Denmark, ³Hebrew University of Jerusalem, Jerusalem, Israel
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 2063 • ACR Convergence 2023
Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers
Saira Sheikh¹, Tessa Englund¹, Andrew Simkus², Nicole Wanty³, Annie McNeill⁴, Kristen Holtz⁴, Tenesha Hood⁵, Starla Blanks⁶, Maria Allen⁷ and Allen Anandarajah⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²KDH Research & Communication, Asheville, NC, ³KDH Research & Communication, Marietta, GA, ⁴KDH Research & Communication, Atlanta, GA, ⁵ACR, Atlanta, GA, ⁶American College of Rheumatology, Atlanta, GA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology's (ACR) Training to Increase Minority Enrollment…
Abstract Number: 2269 • ACR Convergence 2023
Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study
Amelia Holloway¹, Sook Yan Lee², Elena Nikiphorou³, Ioannis Parodis⁴, Simone Appenzeller⁵, Naveen R⁶, Jessica Day⁷, Mrudula Joshi⁸, Sreoshy Saha⁹, Syahrul Sazliyana Shaharir¹⁰, Wanruchada Katchamart¹¹, Phonpen Akarawatcharangura Goo¹², Lisa Traboco¹³, Yi-Ming Chen¹⁴, Parikshit Sen¹⁵, James Lilleker¹⁶, Arvind Nune¹⁷, John Pauling¹⁸, Ai Lyn Tan¹⁹, Nelly Ziade²⁰, Marcin Milchert²¹, Abraham Edgar Gracia-Ramos²², Carlo Caballero²³, COVAD Study Group²⁴, Vikas Agarwal⁶, Rohit Aggarwal²⁵, Latika Gupta²⁶ and Chris Wincup¹, ¹King's College Hospital, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, United Kingdom, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵UNICAMP, Campinas, Brazil, ⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁷Walter and Eliza Hall Institute, Melbourne, Australia, ⁸Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁹Mymensingh Medical College, Faridpur, Bangladesh, ¹⁰Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000, Cheras, Kuala Lumpur, Malaysia, ¹¹Mahidol University, Bangkok, Thailand, ¹²Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ¹³University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, ¹⁴Taichung Veterans General Hospital, Taichung, Taiwan, ¹⁵Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹⁷Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ¹⁸North Bristol NHS Trust, Bristol, United Kingdom, ¹⁹University of Leeds, Leeds, United Kingdom, ²⁰Saint-Joseph University, Beirut, Lebanon, ²¹Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²²Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ²³Universidad del Norte, Barranquilla, Colombia, ²⁴-, -, ²⁵University of Pittsburgh, Pittsburgh, PA, ²⁶Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Regional disparities in the management of SLE are frequently described. Governance, funding, logistic barriers, and physician choice may be important determinants though data is…
Abstract Number: 2286 • ACR Convergence 2023
Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach
Aaron Howe¹, Anson Li², Kevon Jules², Jeremy Tan², Malek Sadek², Mahta Kakvan³, Vijay Chattu¹, Ali Bani-Fatemi¹, Dennisse Bonilla⁴, Wils Nielsen⁵, Nicole Anderson⁶, J. Antonio Avina-Zubieta⁷, Mary Fox⁸, William Shaw⁹, Derek Haaland¹⁰, Janet Pope¹¹, Paul R. Fortin¹², Kathleen Bingham⁴, Nathalie Rozenbojm⁴, Christine Peschken¹³, Jiandong Su⁴, Jennifer Reynolds¹⁴, Catherine Ivory¹⁵, Dafna Gladman¹⁶, Murray Urowitz¹⁷, Francisco Sanchez-Guerrero¹⁸, Lily Lim¹³, Stephanie Keeling¹⁹, Ana Soberanis¹, Patti Katz²⁰, Zahi Touma¹ and Behdin Nowrouzi-Kia¹, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Restore Lab, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Markham, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁷Arthritis Research Canada, Vancouver, BC, Canada, ⁸York University, Toronto, ON, Canada, ⁹University of Connecticut School of Medicine, Farmington, CT, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of British Columbia, Vancouver, BC, Canada, ¹⁵The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ¹⁸University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁹University of Alberta, Edmonton, AB, Canada, ²⁰University of California San Francisco, San Rafael, CA
Background/Purpose: Work participation meaningfully influences mental wellbeing, health-related quality of life, and disease-related outcomes in individuals with systematic lupus erythematosus (SLE). Previous studies estimate that…
Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Jaime Vondenberg¹, Chao Zhang¹ and Emily Littlejohn², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…
Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Clara Moriano Morales¹, Jaime Calvo- Alén², Iñigo Rúa-Figueroa³, MARIA ELVIRA DIEZ ALVAREZ¹, Cristina Bermúdez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Esther Uriarte Isacelaya¹³, carlos Marras Fernández-Cid¹⁴, Carlos Montilla-Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, PALOMA VELA¹⁹, Alina Boteanu²⁰, Javier Narvaez²¹, Victor Martinez-Taboada²², Blanca Hernández-Cruz²³, Jose Luis Andreu-Sánchez²⁴, José Ángel Hernández Beriain²⁵, Lorena Expósito²⁶, Raúl Menor-Almagro²⁷, Mónica Ibáñez-Barceló²⁸, Ivan Castellvi²⁹, Carles Galisteo³⁰, Enrique Raya³¹, Víctor Quevedo-Vila³², Tomás Vazquez-Rodriguez³³, jesús Ibáñez³⁴ and Jose-Maria Pego-Reigosa³⁵, ¹Rheumatology, Hospital Universitario de León, León, Spain, ²Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Bioaraba Research Unit, Vitoria, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Private Practice, Barcelona, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Spanish Health Care Service, Bilbao, Spain, ¹²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁵Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ¹⁶Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁸Rheumatology, Hospital Ourense, Ourense, Spain, ¹⁹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁰Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Rheumatology, Hospital de Canarias, Tenerife, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Rheumatology, Hospital San Cecilio, Granada, Spain, ³²Rheumatology, Hospital Monforte de Lemos, Lugo, Spain, ³³Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³⁴Rheumatology, Hospital Ribera Povisa, Vigo, Spain, ³⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…
Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 2445 • ACR Convergence 2023
Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Dayvia Russell¹, Sandra Sanchez², Evelyn Bruner² and Jim Oates², ¹Ralph H. Johnson VA Medical Center, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) constitutes one of the most severe manifestations of systemic lupus erythematosus (SLE). Evidence points to endothelial nitric oxide synthase (eNOS) uncoupling,…
Abstract Number: 2500 • ACR Convergence 2023
Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Jessica Williams², Hilton Mozee¹, Cristina Drenkard¹ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Suicidal ideation is more common in SLE than in other chronic diseases. Targeted interventions are needed to reduce morbidity and mortality. Bandura’s theory of…
Abstract Number: 2590 • ACR Convergence 2023
Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE)
Christopher Leung¹, Waqas Tahir², Yenny Rosli³, Sarah Lieber⁴, Una Makris⁵, Radjiv Goulabchand⁶, Siddharth Singh⁷ and Namrata Singh⁸, ¹Georgetown University School of Medicine, Washington, DC, ²Mayo Clinic, Jacksonville, FL, ³University of Washington, Seattle, WA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶University of California San Diego, La Jolla, CA, ⁷University of California San Diego, San Diego, CA, ⁸University of Washington, Bellevue, WA
Background/Purpose: SLE has one of the highest 30-day hospital readmission rates among chronic conditions1. Frailty is common2 and associated with hospitalization3 in SLE, but whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].